Shanghai Junshi Bioscience
1877 · HKEX
Public Market Listing
Live quotes, historical charts, and market capitalization for Shanghai Junshi Bioscience are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(8 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerBiliary Tract CancerNasopharyngeal Carcinoma Cholangiocarcinoma | |
| Phase 3 | PI3K-alpha (mutant-selective)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | PD-1 + VEGFAMultispecific antibody | Non-Small Cell Lung CancerHepatocellular CarcinomaBreast Cancer | |
Ongericimab(Junshida) | Phase 3 | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular Disease |
| Phase 3 | IL-17AMonoclonal antibody | Psoriasis | |
| Phase 2 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 2 | EGFR + HER3Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1 | PD-1 (anchoring) / IL-2Rβγ (cis-activation)Protein / enzyme therapeutic | Non-Small Cell Lung Cancer |
Upcoming events
(22 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
2027 (14)
February 2027 (1)
March 2027 (1)
What to watch
April 2027 (1)
May 2027 (2)
June 2027 (1)
What to watch
July 2027 (1)
What to watch
November 2027 (2)
December 2027 (5)
2028 (3)
March 2028 (1)
April 2028 (1)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent